Previous studies have “reported on hearing loss associated with the administration of platinum compounds in patients undergoing active treatment for testicular or head and neck cancer,” but “extremely limited information is available on taxane-induced ototoxicity,” explain the study authors in BMJ Supportive & Palliative Care .

And she concluded: “These results establish HER2-low metastatic breast cancer as a targetable population of breast cancer, with [T-DXd] as a new standard of care in this setting.

Incorporating geriatric assessment-guided management into the care of older patients receiving anticancer therapy could reduce the risk for treatment toxicity and falls as well as polypharmacy, suggests a cluster randomized controlled trial.

The recommendations are based on available evidence and expert opinion, and cover all aspects of metastatic breast cancer care, including diagnosis, staging, risk assessment, treatment, disease monitoring, and palliative care.

About half (48%) of the patients had not received any palliative chemotherapy and 70% had been treated with CDK4/6 inhibitors.

“This is especially important in the context of systemic therapy with palliative intent, as the goals of therapy may evolve over the course of disease to prioritize QOL over quantity of life.”

Switching palliative radiation for high-dose radical hemi-thoracic radiotherapy significantly increases 2-year overall survival among patients with a new diagnosis of malignant pleural mesothelioma, delegates were told at the ESTRO 38 meeting in Milan, Italy.

Researchers have been unable to show that single-dose radiotherapy is not inferior to multifraction radiotherapy in terms of ambulatory status in patients with metastatic prostate, lung, or breast cancer and spinal cord or cauda equina compression.

The study included data from more than 8000 validated HRQoL questionnaires collected via four multicenter, prospective, nonintervention registries of patients with metastatic pancreatic (34.9%), colorectal (30.3%), breast (20.1%), and lung (14.7%) cancer who were recruited at the start of first-line systemic, palliative treatment.